Kornitzer Capital Management Inc. KS Has $10.53 Million Stake in Zoetis Inc. (NYSE:ZTS)

Kornitzer Capital Management Inc. KS raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 0.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 168,850 shares of the company’s stock after buying an additional 1,385 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Zoetis were worth $10,533,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of ZTS. Macquarie Group Ltd. boosted its position in shares of Zoetis by 13.2% in the fourth quarter. Macquarie Group Ltd. now owns 144,492 shares of the company’s stock worth $7,734,000 after buying an additional 16,860 shares during the period. Chevy Chase Trust Holdings Inc. boosted its position in shares of Zoetis by 2.6% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 426,303 shares of the company’s stock worth $22,751,000 after buying an additional 10,744 shares during the period. CENTRAL TRUST Co boosted its position in shares of Zoetis by 1.9% in the first quarter. CENTRAL TRUST Co now owns 2,664 shares of the company’s stock worth $142,000 after buying an additional 49 shares during the period. Fulton Bank N.A. boosted its position in shares of Zoetis by 35.8% in the first quarter. Fulton Bank N.A. now owns 5,554 shares of the company’s stock worth $296,000 after buying an additional 1,463 shares during the period. Finally, New England Research & Management Inc. boosted its position in shares of Zoetis by 56.1% in the first quarter. New England Research & Management Inc. now owns 29,268 shares of the company’s stock worth $1,562,000 after buying an additional 10,523 shares during the period. 92.70% of the stock is owned by institutional investors.

Shares of Zoetis Inc. (ZTS) traded up 1.69% during trading on Monday, reaching $60.74. 2,475,394 shares of the company’s stock traded hands. Zoetis Inc. has a one year low of $46.86 and a one year high of $63.85. The stock has a market cap of $29.71 billion, a P/E ratio of 34.34 and a beta of 1.02. The company has a 50 day moving average price of $62.20 and a 200-day moving average price of $58.00.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting analysts’ consensus estimates of $0.53. The business had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the company earned $0.49 EPS. On average, equities research analysts expect that Zoetis Inc. will post $2.34 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “[[title]]” was originally posted by [[site]] and is owned by of [[site]]. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at [[permalink]].

ZTS has been the subject of a number of recent research reports. BMO Capital Markets reissued a “buy” rating and set a $60.00 price target on shares of Zoetis in a research report on Thursday, May 4th. Jefferies Group LLC lifted their target price on shares of Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, May 9th. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $67.00 target price for the company in a report on Wednesday, May 10th. Credit Suisse Group lifted their target price on shares of Zoetis from $61.00 to $67.00 and gave the stock an “outperform” rating in a report on Wednesday, May 24th. Finally, CL King started coverage on shares of Zoetis in a report on Friday, May 26th. They issued a “buy” rating and a $71.00 target price for the company. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $64.78.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.